{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutant LRRK2 exhibits lower Akt1-phosphorylation activity than wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism by showing that mutant LRRK2 has lower Akt1-phosphorylation activity compared to wild-type LRRK2, suggesting a potential pathogenic role."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Recombinant His-Akt1 (native) was incubated with recombinant GST-LRRK2 of the wild-type (WT), G2019S mutant, I2020T mutant, or R1441C mutant in the presence of cold c-ATP. The phosphorylated Akt1 was subjected to Western analysis using antibodies specific to phospho-Akt1 (S473).",
          "judgment": "Yes",
          "reasoning": "The assay measures Akt1 phosphorylation, which is a standard technique in the field to assess kinase activity and its potential pathogenic effects.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The assay includes wild-type LRRK2 as a control, and the results are compared using statistical analysis (one-way ANOVA, n = 3).",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Graphical representation of the Akt1 (S473) phosphorylation level. Stars represent statistical comparisons by one-way ANOVA (n = 3); ⁄⁄ : p < 0.005.",
          "judgment": "Yes",
          "reasoning": "The statistical analysis shows significant differences in Akt1 phosphorylation levels between wild-type and mutant LRRK2 (p < 0.005). This suggests a strong functional impact."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S mutant LRRK2 shows significantly lower Akt1-phosphorylation activity compared to wild-type LRRK2, with strong statistical support (p < 0.005). This provides supporting evidence for the pathogenicity of the G2019S mutation."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutant LRRK2 exhibits lower Akt1-phosphorylation activity than wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism by showing that mutant LRRK2 has lower Akt1-phosphorylation activity compared to wild-type LRRK2, suggesting a potential pathogenic role."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Recombinant His-Akt1 (native) was incubated with recombinant GST-LRRK2 of the wild-type (WT), G2019S mutant, I2020T mutant, or R1441C mutant in the presence of cold c-ATP. The phosphorylated Akt1 was subjected to Western analysis using antibodies specific to phospho-Akt1 (S473).",
          "judgment": "Yes",
          "reasoning": "The assay measures Akt1 phosphorylation, which is a standard technique in the field to assess kinase activity and its potential pathogenic effects.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The assay includes wild-type LRRK2 as a control, and the results are compared using statistical analysis (one-way ANOVA, n = 3).",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Graphical representation of the Akt1 (S473) phosphorylation level. Stars represent statistical comparisons by one-way ANOVA (n = 3); ⁄⁄ : p < 0.005.",
          "judgment": "Yes",
          "reasoning": "The statistical analysis shows significant differences in Akt1 phosphorylation levels between wild-type and mutant LRRK2 (p < 0.005). This suggests a strong functional impact."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The I2020T mutant LRRK2 shows significantly lower Akt1-phosphorylation activity compared to wild-type LRRK2, with strong statistical support (p < 0.005). This provides supporting evidence for the pathogenicity of the I2020T mutation."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutant LRRK2 exhibits lower Akt1-phosphorylation activity than wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism by showing that mutant LRRK2 has lower Akt1-phosphorylation activity compared to wild-type LRRK2, suggesting a potential pathogenic role."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Recombinant His-Akt1 (native) was incubated with recombinant GST-LRRK2 of the wild-type (WT), G2019S mutant, I2020T mutant, or R1441C mutant in the presence of cold c-ATP. The phosphorylated Akt1 was subjected to Western analysis using antibodies specific to phospho-Akt1 (S473).",
          "judgment": "Yes",
          "reasoning": "The assay measures Akt1 phosphorylation, which is a standard technique in the field to assess kinase activity and its potential pathogenic effects.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The assay includes wild-type LRRK2 as a control, and the results are compared using statistical analysis (one-way ANOVA, n = 3).",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Graphical representation of the Akt1 (S473) phosphorylation level. Stars represent statistical comparisons by one-way ANOVA (n = 3); ⁄⁄ : p < 0.005.",
          "judgment": "Yes",
          "reasoning": "The statistical analysis shows significant differences in Akt1 phosphorylation levels between wild-type and mutant LRRK2 (p < 0.005). This suggests a strong functional impact."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1441C mutant LRRK2 shows significantly lower Akt1-phosphorylation activity compared to wild-type LRRK2, with strong statistical support (p < 0.005). This provides supporting evidence for the pathogenicity of the R1441C mutation."
    }
  ]
}